Gilead Sciences (GILD) 82.05 $GILD
After Yesterday's Rally of 1.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 14 mins ago
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $80.50 to a high of $82.10. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $81.61 on volume of 10.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
AstraZeneca Rejects Pfizer's Final Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 10:07AM CDT
AstraZeneca (AZN) announced that it has rejected Pfizer's (PFE) latest takeover proposal.
Early Glance: Biotechnology companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Gilead Sciences (GILD) Approaches New Upside Target of $81.91
Comtex SmarTrend(R) - Mon May 19, 9:19AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $80.29 today and have reached the first resistance level of $81.35. Investors may be interested in a cross of the next upside pivot targets of $81.91 and $83.53.
1 Biotech Refusing to Stick Its Neck Out
Cory Renauer, The Motley Fool - Motley Fool - Mon May 19, 8:30AM CDT
Pharmacyclics confused the market earlier this month with some shockingly conservative Imbruvica guidance. Sales of the breakthrough leukemia therapy have rocketed upwards since its launch late last year, so the suggestion that it will level off...
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
3 Companies Frightened by This Medicare Study
Todd Campbell, The Motley Fool - Motley Fool - Sun May 18, 6:05AM CDT
Everyone knows that medical costs are soaring, and that those costs present one of the biggest financial challenges to the next generation. But far fewer know that one of the biggest drug buyers, the Centers for Medicare and Medicaid Services, or...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Can CVS Overcome the Drug Poised to "Break the Country?"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Consider the following quotes: "What they have done with this particular drug will break the country." "We expect the impact to be minimal for this year." These two quotes, the first from Express Scripts ' chief medical officer Steven...
Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress.
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin).
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study.
XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 10:50AM CDT
XenoPort, Inc. (XNPT) announced a deal with Reckitt Benckiser Pharmaceuticals for the development and commercialization of XenoPort's arbaclofen placarbil.
Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 8:46AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, with shares rising over 19% on the day.
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,...
After Yesterday's Rally of 1.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 14 mins ago
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $80.50 to a high of $82.10. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $81.61 on volume of 10.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
AstraZeneca Rejects Pfizer's Final Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 10:07AM CDT
AstraZeneca (AZN) announced that it has rejected Pfizer's (PFE) latest takeover proposal.
Early Glance: Biotechnology companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Gilead Sciences (GILD) Approaches New Upside Target of $81.91
Comtex SmarTrend(R) - Mon May 19, 9:19AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $80.29 today and have reached the first resistance level of $81.35. Investors may be interested in a cross of the next upside pivot targets of $81.91 and $83.53.
1 Biotech Refusing to Stick Its Neck Out
Cory Renauer, The Motley Fool - Motley Fool - Mon May 19, 8:30AM CDT
Pharmacyclics confused the market earlier this month with some shockingly conservative Imbruvica guidance. Sales of the breakthrough leukemia therapy have rocketed upwards since its launch late last year, so the suggestion that it will level off...
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
3 Companies Frightened by This Medicare Study
Todd Campbell, The Motley Fool - Motley Fool - Sun May 18, 6:05AM CDT
Everyone knows that medical costs are soaring, and that those costs present one of the biggest financial challenges to the next generation. But far fewer know that one of the biggest drug buyers, the Centers for Medicare and Medicaid Services, or...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Can CVS Overcome the Drug Poised to "Break the Country?"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Consider the following quotes: "What they have done with this particular drug will break the country." "We expect the impact to be minimal for this year." These two quotes, the first from Express Scripts ' chief medical officer Steven...
Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress.
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin).
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study.
XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 10:50AM CDT
XenoPort, Inc. (XNPT) announced a deal with Reckitt Benckiser Pharmaceuticals for the development and commercialization of XenoPort's arbaclofen placarbil.
Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 8:46AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, with shares rising over 19% on the day.
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,...
